Nicox S.A. (NYSE Euronext Paris: COX) today announced the completion of the acquisition of Eupharmed, a privately-held Italian ophthalmic company. This acquisition is part of Nicox’s strategy to establish sales infrastructure in the five major European markets and in the United States as it provides an established sales and marketing platform in Italy together with a broad portfolio of marketed eye care products.
For more information, please refer to:
- Press release dated November 26, 2013: Nicox establishes commercial operations in Italy through acquisition of Eupharmed
- Press release dated December 5, 2013 (Art. 12 of the AMF instruction 2005-11) (in French): Emission par Nicox de 1.351.351 actions et de 1.500.000 bons d’attribution d’actions en rémunération de l’apport de la totalité du capital de la société Eupharmed